Statements (60)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:activities |
insulin receptor agonist
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:legislation
gptkb:2015 gptkb:United_States |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Tresiba
|
| gptkbp:class |
antidiabetic agent
|
| gptkbp:climax |
no pronounced peak
|
| gptkbp:clinical_trial |
gptkb:Company
Phase 3 basal insulin therapy effective in controlling blood sugar |
| gptkbp:contraindication |
severe liver disease
hypersensitivity to insulin |
| gptkbp:developed_by |
gptkb:Novo_Nordisk
|
| gptkbp:dosage_form |
once daily
based on blood glucose levels |
| gptkbp:duration |
up to 42 hours
|
| gptkbp:education |
importance of injection technique
|
| gptkbp:feedback |
positive feedback on flexibility
|
| gptkbp:form |
pen, vial
|
| gptkbp:formulation |
gptkb:software_framework
long-acting insulin |
| gptkbp:healthcare |
injectable solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
insulin degludec
|
| gptkbp:ingredients |
gptkb:insulin_degludec
|
| gptkbp:interacts_with |
beta-blockers
thiazolidinediones |
| gptkbp:is_compared_to |
longer duration than insulin glargine
|
| gptkbp:is_monitored_by |
regular blood glucose monitoring required
|
| gptkbp:is_used_for |
diabetes management
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:market |
2015 in the US
2015 in Europe |
| gptkbp:marketed_as |
gptkb:Tresiba
|
| gptkbp:pharmacokinetics |
glucose lowering effect
prolonged absorption |
| gptkbp:population |
adults with type 2 diabetes
adults with type 1 diabetes |
| gptkbp:premiered_on |
1 hour
|
| gptkbp:price |
varies by region and insurance
|
| gptkbp:provides_information_on |
recommended for type 1 and type 2 diabetes
|
| gptkbp:regulatory_compliance |
gptkb:FDA
gptkb:EMA |
| gptkbp:research_focus |
long-term safety and efficacy
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:sales |
increasing annually
|
| gptkbp:side_effect |
allergic reactions
weight gain injection site reactions hypoglycemia |
| gptkbp:social_structure |
hexadecandioic acid
|
| gptkbp:storage |
refrigerated
|
| gptkbp:type_of_care |
improved adherence due to flexibility
|
| gptkbp:website |
abdomen, thigh, upper arm
|
| gptkbp:bfsParent |
gptkb:insulin_analogs
gptkb:Tresiba |
| gptkbp:bfsLayer |
5
|